Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic‐phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors von Cortes, J., Digumarti, R., Parikh, P.M., Wetzler, M., Lipton, J.H., Hochhaus, A., Craig, A.R., Benichou, A.‐C., Nicolini, F.E., Kantarjian, H.M.

Volltext

Impact of aberrant DNA methylation patterns including CYP1B1 methylation in adolescents and young adults with acute lymphocytic leukemia von DiNardo, C.D., Gharibyan, V., Yang, H., Wei, Y., Pierce, S., Kantarjian, H.M., Garcia‐Manero, G., Rytting, M.

Volltext

Moving toward individualized target-based therapies in acute myeloid leukemia von Bazinet, A., Kantarjian, H.M.

Volltext

OP13 Novel agents in acute myeloid leukemia (AML) von Kantarjian, H.M

Volltext

S01 Imatinib mesylate in chronic myeloid leukemia (CML). 5-year update of the IRIS trial von Kantarjian, H.M

Volltext

Enasidenib (AG-221), A Selective Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, In Patients with Myelodysplastic Syndromes (MDS) von Stein, E.M, Fathi, A.T, DiNardo, C.D, Pollyea, D.A, Swords, R.T, Roboz, G.J, Collins, R, Sekeres, M.A, Stone, R.M, Attar, E.C, Tosolini, A, Xu, Q, Amatangelo, M, Gupta, I, Knight, R.D, de Botton, S, Tallman, M.S, Kantarjian, H.M

Volltext

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial von Hochhaus, A, Saglio, G, Hughes, T P, Larson, R A, Kim, D-W, Issaragrisil, S, le Coutre, P D, Etienne, G, Dorlhiac-Llacer, P E, Clark, R E, Flinn, I W, Nakamae, H, Donohue, B, Deng, W, Dalal, D, Menssen, H D, Kantarjian, H M

Volltext

Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up von Larson, R A, Hochhaus, A, Hughes, T P, Clark, R E, Etienne, G, Kim, D-W, Flinn, I W, Kurokawa, M, Moiraghi, B, Yu, R, Blakesley, R E, Gallagher, N J, Saglio, G, Kantarjian, H M

Volltext

Phase IB study of the FLT3 kinase inhibitor midostaurin with chemotherapy in younger newly diagnosed adult patients with acute myeloid leukemia von Stone, R M, Fischer, T, Paquette, R, Schiller, G, Schiffer, C A, Ehninger, G, Cortes, J, Kantarjian, H M, DeAngelo, D J, Huntsman-Labed, A, Dutreix, C, del Corral, A, Giles, F

Volltext

Irradiated Extramedullary Acute Myeloid Leukemia Increases Survival in a Leukemic Mouse Model von Saenz, F.R., Dabaja, B., Fang, G., Daver, N., Kantarjian, H.M., Spiotto, M.T.

Volltext

Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center von Walter, R B, Othus, M, Burnett, A K, Löwenberg, B, Kantarjian, H M, Ossenkoppele, G J, Hills, R K, Ravandi, F, Pabst, T, Evans, A, Pierce, S R, Vekemans, M-C, Appelbaum, F R, Estey, E H

Volltext

Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study von Giles, F J, le Coutre, P D, Pinilla-Ibarz, J, Larson, R A, Gattermann, N, Ottmann, O G, Hochhaus, A, Radich, J P, Saglio, G, Hughes, T P, Martinelli, G, Kim, D-W, Novick, S, Gillis, K, Fan, X, Cortes, J, Baccarani, M, Kantarjian, H M

Volltext

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib von Hochhaus, A, Baccarani, M, Deininger, M, Apperley, J F, Lipton, J H, Goldberg, S L, Corm, S, Shah, N P, Cervantes, F, Silver, R T, Niederwieser, D, Stone, R M, Dombret, H, Larson, R A, Roy, L, Hughes, T, Müller, M C, Ezzeddine, R, Countouriotis, A M, Kantarjian, H M

Volltext

Myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN, U): natural history and clinical outcome by treatment strategy von DiNardo, C D, Daver, N, Jain, N, Pemmaraju, N, Bueso-Ramos, C, Yin, C C, Pierce, S, Jabbour, E, Cortes, J E, Kantarjian, H M, Garcia-Manero, G, Verstovsek, S

Volltext

MicroRNAs and noncoding RNAs in hematological malignancies: molecular, clinical and therapeutic implications von Fabbri, M, Garzon, R, Andreeff, M, Kantarjian, H M, Garcia-Manero, G, Calin, G A

Volltext

Dorsal Column Myelopathy Following Intrathecal Chemotherapy for Leukemia von Schrank, B.R., Manzar, G.S., Wu, S.Y., Gunther, J.R., Fang, P., Jabbour, E.J., Lim, T.Y., Daver, N.G., Cykowski, M.D., Fuller, G.N., Cachia, D., Kamiya-Matsuoka, C., Woodman, K.H., DiNardo, C.D., Jain, N., Short, N.J., Sasaki, K., Dabaja, B., Kantarjian, H.M., Pinnix, C.C.

Volltext

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results von le Coutre, P D, Giles, F J, Hochhaus, A, Apperley, J F, Ossenkoppele, G J, Blakesley, R, Shou, Y, Gallagher, N J, Baccarani, M, Cortes, J, Kantarjian, H M

Volltext

Differential impact of additional chromosomal abnormalities in myeloid vs lymphoid blast phase of chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy von Chen, Z, Cortes, J E, Jorgensen, J L, Wang, W, Yin, C C, You, M J, Jabbour, E, Kantarjian, H M, Medeiros, L J, Hu, S

Volltext

Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phase von Giles, F J, Kantarjian, H M, le Coutre, P D, Baccarani, M, Mahon, F-X, Blakesley, R E, Gallagher, N J, Gillis, K, Goldberg, S L, Larson, R A, Hochhaus, A, Ottmann, O G

Volltext

Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and pa... von Jabbour, E, Hochhaus, A, Cortes, J, La Rosée, P, Kantarjian, H M

Volltext